Floatz logo

ELGEMTUMAB

Advanced HER2-positive Breast Cancer or Gastric Cancer

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced HER2-positive Breast Cancer or Gastric Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

ELGEMTUMAB is also rated in:

HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
47 / 100
View asset →
HER2 positive breast carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →